Cargando…

Risk factors for herpes zoster in Korean patients with rheumatoid arthritis treated with JAK inhibitor: a nested case–control study

OBJECTIVE: To determine the risk of herpes zoster (HZ) in Korean patients with rheumatoid arthritis (RA) receiving Janus kinase inhibitors (JAKis). METHODS: We performed a nested case–control study with 1:10 matching for sex and age using single-centre prospective cohorts of patients with RA receivi...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Yeo-Jin, Cho, Soo-Kyung, Kim, Hyoungyoung, Kim, Hye Won, Nam, Eunwoo, Choi, Chan-Bum, Kim, Tae-Hwan, Jun, Jae-Bum, Bae, Sang-Cheol, Yoo, Dae Hyun, Sung, Yoon-Kyoung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8804703/
https://www.ncbi.nlm.nih.gov/pubmed/35091461
http://dx.doi.org/10.1136/rmdopen-2021-001892
_version_ 1784643139121709056
author Song, Yeo-Jin
Cho, Soo-Kyung
Kim, Hyoungyoung
Kim, Hye Won
Nam, Eunwoo
Choi, Chan-Bum
Kim, Tae-Hwan
Jun, Jae-Bum
Bae, Sang-Cheol
Yoo, Dae Hyun
Sung, Yoon-Kyoung
author_facet Song, Yeo-Jin
Cho, Soo-Kyung
Kim, Hyoungyoung
Kim, Hye Won
Nam, Eunwoo
Choi, Chan-Bum
Kim, Tae-Hwan
Jun, Jae-Bum
Bae, Sang-Cheol
Yoo, Dae Hyun
Sung, Yoon-Kyoung
author_sort Song, Yeo-Jin
collection PubMed
description OBJECTIVE: To determine the risk of herpes zoster (HZ) in Korean patients with rheumatoid arthritis (RA) receiving Janus kinase inhibitors (JAKis). METHODS: We performed a nested case–control study with 1:10 matching for sex and age using single-centre prospective cohorts of patients with RA receiving targeted therapy in Korea. Then we performed conditional logistic regression analyses to determine the risk associated with JAKi use compared with biologic disease-modifying antirheumatic drug (bDMARD) use, with adjusting for various factors. We also used logistic regression analysis to identify other risk factors for the development of HZ in JAKi users. RESULTS: From a total of 1147 patients, 61 cases and 610 matched controls were selected. In conditional logistic regression analysis, JAKi use did not increase the risk of HZ development (OR 1.35, 95% CI 0.70 to 2.61) after adjusting for other factors. Rather, duration of RA less than 10 years (OR 0.54, 95% CI 0.30 to 0.97) and having had three or more previous targeted therapies (OR 5.29, 95% CI 1.45 to 19.31) were risk factors for HZ. Among JAKi users, higher disease activity score 28-erythrocyte sedimentation rate (DAS28-ESR) (OR 1.44, 95% CI 1.06 to 1.97) was identified as a risk factor in addition to three or more previous targeted therapies (OR 10.12, 95% CI 1.92 to 53.49). CONCLUSIONS: The number of previous targeted therapies, but not JAKi use, was identified as a risk factor for HZ development in Korean patients with RA in a real-world setting. High disease activity was an additional risk factor for JAKi users.
format Online
Article
Text
id pubmed-8804703
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-88047032022-02-07 Risk factors for herpes zoster in Korean patients with rheumatoid arthritis treated with JAK inhibitor: a nested case–control study Song, Yeo-Jin Cho, Soo-Kyung Kim, Hyoungyoung Kim, Hye Won Nam, Eunwoo Choi, Chan-Bum Kim, Tae-Hwan Jun, Jae-Bum Bae, Sang-Cheol Yoo, Dae Hyun Sung, Yoon-Kyoung RMD Open Infections OBJECTIVE: To determine the risk of herpes zoster (HZ) in Korean patients with rheumatoid arthritis (RA) receiving Janus kinase inhibitors (JAKis). METHODS: We performed a nested case–control study with 1:10 matching for sex and age using single-centre prospective cohorts of patients with RA receiving targeted therapy in Korea. Then we performed conditional logistic regression analyses to determine the risk associated with JAKi use compared with biologic disease-modifying antirheumatic drug (bDMARD) use, with adjusting for various factors. We also used logistic regression analysis to identify other risk factors for the development of HZ in JAKi users. RESULTS: From a total of 1147 patients, 61 cases and 610 matched controls were selected. In conditional logistic regression analysis, JAKi use did not increase the risk of HZ development (OR 1.35, 95% CI 0.70 to 2.61) after adjusting for other factors. Rather, duration of RA less than 10 years (OR 0.54, 95% CI 0.30 to 0.97) and having had three or more previous targeted therapies (OR 5.29, 95% CI 1.45 to 19.31) were risk factors for HZ. Among JAKi users, higher disease activity score 28-erythrocyte sedimentation rate (DAS28-ESR) (OR 1.44, 95% CI 1.06 to 1.97) was identified as a risk factor in addition to three or more previous targeted therapies (OR 10.12, 95% CI 1.92 to 53.49). CONCLUSIONS: The number of previous targeted therapies, but not JAKi use, was identified as a risk factor for HZ development in Korean patients with RA in a real-world setting. High disease activity was an additional risk factor for JAKi users. BMJ Publishing Group 2022-01-28 /pmc/articles/PMC8804703/ /pubmed/35091461 http://dx.doi.org/10.1136/rmdopen-2021-001892 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Infections
Song, Yeo-Jin
Cho, Soo-Kyung
Kim, Hyoungyoung
Kim, Hye Won
Nam, Eunwoo
Choi, Chan-Bum
Kim, Tae-Hwan
Jun, Jae-Bum
Bae, Sang-Cheol
Yoo, Dae Hyun
Sung, Yoon-Kyoung
Risk factors for herpes zoster in Korean patients with rheumatoid arthritis treated with JAK inhibitor: a nested case–control study
title Risk factors for herpes zoster in Korean patients with rheumatoid arthritis treated with JAK inhibitor: a nested case–control study
title_full Risk factors for herpes zoster in Korean patients with rheumatoid arthritis treated with JAK inhibitor: a nested case–control study
title_fullStr Risk factors for herpes zoster in Korean patients with rheumatoid arthritis treated with JAK inhibitor: a nested case–control study
title_full_unstemmed Risk factors for herpes zoster in Korean patients with rheumatoid arthritis treated with JAK inhibitor: a nested case–control study
title_short Risk factors for herpes zoster in Korean patients with rheumatoid arthritis treated with JAK inhibitor: a nested case–control study
title_sort risk factors for herpes zoster in korean patients with rheumatoid arthritis treated with jak inhibitor: a nested case–control study
topic Infections
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8804703/
https://www.ncbi.nlm.nih.gov/pubmed/35091461
http://dx.doi.org/10.1136/rmdopen-2021-001892
work_keys_str_mv AT songyeojin riskfactorsforherpeszosterinkoreanpatientswithrheumatoidarthritistreatedwithjakinhibitoranestedcasecontrolstudy
AT chosookyung riskfactorsforherpeszosterinkoreanpatientswithrheumatoidarthritistreatedwithjakinhibitoranestedcasecontrolstudy
AT kimhyoungyoung riskfactorsforherpeszosterinkoreanpatientswithrheumatoidarthritistreatedwithjakinhibitoranestedcasecontrolstudy
AT kimhyewon riskfactorsforherpeszosterinkoreanpatientswithrheumatoidarthritistreatedwithjakinhibitoranestedcasecontrolstudy
AT nameunwoo riskfactorsforherpeszosterinkoreanpatientswithrheumatoidarthritistreatedwithjakinhibitoranestedcasecontrolstudy
AT choichanbum riskfactorsforherpeszosterinkoreanpatientswithrheumatoidarthritistreatedwithjakinhibitoranestedcasecontrolstudy
AT kimtaehwan riskfactorsforherpeszosterinkoreanpatientswithrheumatoidarthritistreatedwithjakinhibitoranestedcasecontrolstudy
AT junjaebum riskfactorsforherpeszosterinkoreanpatientswithrheumatoidarthritistreatedwithjakinhibitoranestedcasecontrolstudy
AT baesangcheol riskfactorsforherpeszosterinkoreanpatientswithrheumatoidarthritistreatedwithjakinhibitoranestedcasecontrolstudy
AT yoodaehyun riskfactorsforherpeszosterinkoreanpatientswithrheumatoidarthritistreatedwithjakinhibitoranestedcasecontrolstudy
AT sungyoonkyoung riskfactorsforherpeszosterinkoreanpatientswithrheumatoidarthritistreatedwithjakinhibitoranestedcasecontrolstudy